Mucormycosis: An Emerging Challenge among COVID-19 Patients

Abstract

Mucormycosis is a rare angio-invasive opportunistic fungal infection that has become an emerging challenge among COVID-19 patients. The higher incidence of mucormycosis among COVID-19 patients has been attributed to hypoxia, pre-existing or steroid induced diabetes, diabetic ketoacidosis, increased ferritin levels, and SARS-CoV-2 or steroid mediated immunosuppression. Other contributing factors include prolonged hospitalization with or without use of mechanical ventilators.The epidemiology and etiopathogenesis of this disease are still evolving. Once infected, the disease progresses rapidly. This disease requires hospital based treatment under supervision with use of anti-fungal medications, treatment of underlying factors and surgical debridement. The treatment outcome depends upon site of infection, extent of spread, overall health, underlying diseases, degree of immunosuppression, the rapidity of diagnosis and treatment.